Anecortave (retaane) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Anecortave (rINN) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity. If it is approved, it will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane. No development has been reported since 2010.   Wikipedia

Chemistry

  • SMILES: CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C
  • InChIKey: YUWPMEXLKGOSBF-GACAOOTBSA-N
  • Mol. Mass: 386.49
  • ALogP: 3.3
  • ChEMBL Molecule:
    anecortave acetate  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

4,9(11)-pregnadien-17alpha,21-diol-3,20-dione-21-acetate | al 3789 | al-3789 | anecortave | anecortave acetate | retaane

Organizations (7)

Research & Development (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (18)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Central Serous Chorioretinopathy (Phase 1/Phase 2)

Communicable Diseases (Phase 2)

Diabetic Retinopathy (Phase 2)

Eye Diseases (Phase 2)

Eye Injuries (Phase 2)

Glaucoma (Phase 1)

Glaucoma, Open-Angle (Phase 2/Phase 3)

Hypertension (Phase 2/Phase 3)

Inflammation (Phase 2)

Lens Diseases (Phase 2)

Macular Degeneration (Phase 3)

Neovascularization, Pathologic (Phase 2)

Ocular Hypertension (Phase 2)

Retinal Telangiectasis (Phase 2)

Retinal Vein Occlusion (Phase 2)

Telangiectasis (Phase 2)

Uveitis, Posterior (Phase 1)

Wet Macular Degeneration (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial Organizations: 7

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue